Despite comprising only~0.001% of all neurons in the human brain, ventral midbrain dopamine neurons exert a profound influence on human behavior and cognition. As a neuromodulator, dopamine selectively inhibits or enhances synaptic signaling to coordinate neural output for action, attention, and affect. Humans invariably lose brain dopamine during aging, and this can be exacerbated in disease states such as Parkinson's Disease. Further, it is well established in multiple disease states that cell loss is selective for a subset of highly sensitive neurons within the nigrostriatal dopamine tract. Regional differences in dopamine tone are regulated pre-synaptically, with subcircuits of projecting dopamine neurons exhibiting distinct molecular and physiological signatures. Specifically, proteins at dopamine release sites that synthesize and package cytosolic dopamine, modulate its release and reuptake, and alter neuronal excitability show regional differences that provide linkages to the observed sensitivity to neurodegeneration. The aim of this review is to outline the major components of dopamine homeostasis at neurotransmitter release sites and describe the regional differences most relevant to understanding why some, but not all, dopamine neurons exhibit heightened vulnerability to neurodegeneration.
Ventral midbrain dopamine signaling

Dopamine in the brain
Earlier this year a novel theory of dopamine's action in the brain was put forth by Beeler and Kisbye (Beeler and Dreyer, 2019) . Synthesizing elegant in vivo recording data that anatomically maps afferent input signals and dopamine neurons' firing response to stimuli, they argue that the cellular and subcellular specializations of dopamine neurons allow them to act as high volume sampling programs (Tian et al., 2016; Lammel et al., 2014; Watabe-Uchida et al., 2012) . Thusly, coordinated increases in randomly sampled afferent activity signal consensus to dopaminergic subsets; consensus signals when to increase brain dopamine tone to regionally inhibit or disinhibit synaptic signaling and plasticity (Beeler and Dreyer, 2019; Tian et al., 2016; Lammel et al., 2014; Watabe-Uchida et al., 2012) .
Dopamine signaling from the ventral midbrain can be grossly simplified into two components: 1) acting as a neurobiological substrate conveying the timing of salient stimuli, and 2) encoding patterns for selection and execution of goal-oriented movement (Beeler and Dreyer, 2019; Fiorillo et al., 2008; Cui et al., 2013) . This functional bifurcation maps onto the predominant anatomical distinction between midbrain dopamine neurons, the ventral tegmental area (VTA, salience) and substantia nigra pars compacta (SNc, movement) (Albin et al., 1989; Fu et al., 2012) . VTA dopamine neurons comprise the mesocortical and mesolimbic dopamine circuits; these cells increase firing activity to raise dopamine levels in brain areas important for threat or reward recognition and the subsequent learning that would encode an aversive or seeking habit (Baik, 2013) . SNc, or nigrostriatal circuit, dopamine neurons project through the direct and indirect pathways of the basal ganglia, with the ultimate output being neurons in the motor cortex to control goal-oriented movement (Cui et al., 2013) . It is a subset of these nigrostriatal neurons that have been consistently shown to be more sensitive to aging and neurodegeneration (Gibb and Lees, 1991; Hirsch et al., 1988; Surmeier et al., 2017) . Interestingly, these two systems can redistribute encoding between their respective striatal targets: when a learned behavior becomes habitual, the encoding of the task is shunted away from dorsomedial striatum (associative) to the dorsolateral striatum (sensorimotor) (Yin et al., 2009) . Also of note, this neural merging point creates a dovetail in diseases related to dopamine neuron dysfunction. For example: in Parkinson's Disease (PD), a movement disorder induced by degeneration of SNc dopamine neurons, increased prevalence of impulse control disorders has been observed (Eisinger et al., 2019) . Other non-motor symptoms of PD including depression and working-memory are currently under investigation as measurable markers of disease progression and subtype (Yoo et al., 2019; Colon-Perez et al., 2018) . However, the linkages between physiological diversity to shared and distinct facets of dopamine-related disorders are not completely characterized.
In contrast from point-to-point neurotransmission, dopamine signals en masse. Synchronized subcircuits of dopamine neurons establish extracellular concentrations throughout their respective projection area. At terminal fields in the dorsal and ventral striatum, medium spiny neurons (MSNs) express D1-like (Gα s/olf coupled) and/or D2-like (Gα i/o coupled) G-protein coupled receptors (Yung et al., 1995; Calipari et al., 2016; Gertler et al., 2008) . In nigrostriatal circuits, these MSN populations represent the flow of information through the direct pathway (action initiation, D1) and the indirect pathway (action inhibition, D2) respectively (Albin et al., 1989; Bergman et al., 1998) . Within and beyond the striatum, activated D1-like and D2-like receptors modulate adenylyl cyclase activity to facilitate or dampen synaptic signaling respectively (Beaulieu and Gainetdinov, 2011) . Dopamine neurons also express D2 autoreceptors which act as negative feedback agents on cell firing and dopamine release (Ford, 2014; Robinson et al., 2017) . Once activated, D2 autoreceptors reduce dopamine release and promote reuptake by inducing membrane hyperpolarization and reducing Ca 2+ influx (Wu et al., 2002; Lacey et al., 1987) . However, the relative contribution of D2 autoreceptor activity to extracellular dopamine levels varies considerably between species and brain regions (Wu et al., 2002; Beckstead et al., 2007; Cragg and Greenfield, 1997; Courtney et al., 2012) .
Aberrant dopamine signaling has been linked to many psychiatric and neurological disease states including schizophrenia, bipolar disorder, major depressive disorder (MDD), attention deficit and hyperactivity disorder (ADHD), PD, Huntington's disease (HD), and HIV-1 associated neurodegeneration (HAND) (Grace, 2016; Kim et al., 2014; Yang et al., 2018; Hansen et al., 2014; Bernheimer et al., 1973; Miller et al., 2018) . The scope of the current review is to outline release-site vulnerability most relevant to the loss of dopamine neurons in idiopathic PD. Understanding PD-related factors may also provide insight as to why healthy humans appear to display an invariable gradual loss of dopamine tone through aging, albeit with a pattern that is distinct from neuronal loss in PD (Kish et al., 1992) . Additionally,~15% of healthy individuals examined post-mortem exhibit post-mortem PD brain pathology -namely proteinaceous alpha-synuclein aggregates termed Lewy bodies (LBs) -that would suggest the presence of a dopaminergic disorder with no such clinical manifestation (Berg et al., 2014; Dickson et al., 2008; Braak et al., 2003a; Parkkinen et al., 2008) . Despite this, presence of LBs in dopaminergic neurons remains a gold-standard confirmatory symptom in PD, although whether LBs represent cytotoxic aggregates or neuroprotective sequestration bodies remains an active debate (Tompkins and Hill, 1997; Tanaka et al., 2004; Power et al., 2017) . These data obfuscate the roles of proteostatic stress and LB pathology in dopaminergic dysfunction and degeneration, despite numerous linkages between LB-like alpha-synuclein aggregates and neuronal dysfunction and loss in model systems (Subramaniam et al., 2014a; Subramaniam et al., 2014b; Kouroupi et al., 2017; Paillusson et al., 2017; Ludtmann et al., 2018) . Nevertheless, SNc dopamine neurons generally exhibit greater levels of neurodegeneration in human disease and animal models of dopaminergic neurodegeneration (Hirsch et al., 1988; Mosharov et al., 2009; Ekstrand et al., 2007) . Thusly, it stands to reason that some facets of SNc dopaminergic physiology in and of themselves lead to heightened vulnerability and cell death during aging (Surmeier et al., 2017) .
Feed-forward dopamine signaling via intrinsic pacemaking
Dopamine neurons are intrinsic pacemakers, with their slow (2-4 Hz) rhythmic activity first described in the rat SNc by Grace and Bunney in 1984 (Grace and Bunney, 1984a) . It is hypothesized that this feed-forward control of activity has been conserved because a tonic concentration of dopamineirrespective of external stimuliis advantageous should a rapid movement such as predator evasion become necessary with little warning (Surmeier et al., 2017) . Additionally, dopamine neurons can fire in rapid bursts in response to relevant salient stimuli (Grace and Bunney, 1984b) . This transient increase in firing induces a temporally-precise rise in dopamine concentrations allowing a specific stimulus/response to be encoded and, if applicable, entrained. As described earlier, anatomically discrete dopaminergic subcircuits exhibit coordinated rises in firing rates to raise dopamine concentrations in accordance with the timing of afferent input agreement (Beeler and Dreyer, 2019) . This can be easily observed in the context of reward prediction error, during which rewards of greater uncertainty elicit a larger increase in VTA cell firingputatively to strengthen synapses important for the reinforcement of an unexpectedly (i.e. novel) favorable behavior (Fiorillo et al., 2008; Fiorillo et al., 2003) .
SNc and VTA dopamine neurons exhibit fundamental differences with regards to their ionic control of pacemaking activity (Gantz et al., 2018) . In the VTA, slow rhythmic firing is predominantly driven by TTX-insensitive Na + channels and regulated by a dynamic A-type K + current (Khaliq and Bean, 2010; Khaliq and Bean, 2008) . In the SNc however, voltage-gated Ca 2+ channels carry the majority of current that drives pacemaking and frequency is similarly regulated by A-type K + currents (Kang and Kitai, 1993; Mercuri et al., 1994; Liss et al., 2001) . Also of note, SNc and VTA dopamine neurons exhibit different sag-currents in response to hyperpolarization, a key pacemaker current often used to identify dopaminergic neurons as such (Krashia et al., 2017; Tarfa et al., 2017) . Studies in mice have shown that SNc and VTA dopamine neurons exhibit inter-and intra-regional differences in tonic firing rates, with lateral SNc neurons showing the highest firing rate, and medial VTA neurons showing the lowest (Krashia et al., 2017) . Consistent with their basal differences, SNc and VTA dopamine neurons exhibit distinct responses to electrical and pharmacological stimulation ex vivo, but this has been shown to vary across common murine models (namely rats, mice, and guinea pigs) (Cragg and Greenfield, 1997; Courtney et al., 2012; Keath et al., 2007) .
Pacemaker activity has been heavily implicated in SNc dopamine neuron's heightened vulnerability profile (Guzman et al., 2010) . Specifically, it has been shown in mice that pacemaking-induced Ca 2+ influx leads to the generation of reactive oxygen species in the mitochondria of SNc dopamine neurons (Guzman et al., 2010; Guzman et al., 2018; Lieberman et al., 2017; Pacelli et al., 2015) . This reactive oxygen species generation likely underlies the high level of mitochondrial DNA mutations observed in human SNc neurons, which would in turn gradually compromise the energetic competence of the cell (Bender et al., 2006; Bolam and Pissadaki, 2012) . VTA neurons are seemingly spared from this energetic compromise not only because they are less reliant on Ca 2+ channels for pacemaking, but also because they are enriched with the calcium binding protein calbindin (Fu et al., 2012; Khaliq and Bean, 2010; Dopeso-Reyes et al., 2014) . Degeneration-sensitive SNc neurons, in contrast, map to one end of a calbindin expression gradient at which the protein is completely absent (Mosharov et al., 2009; Poulin et al., 2014) . Importantly, the inverse relationship between calbindin expression and degeneration-sensitivity of dopamine neurons has been observed in humans as well as rodents and non-human primates (Dopeso- Reyes et al., 2014; Poulin et al., 2014; Yamada et al., 1990; Liang et al., 1996) . In the SNc of mice, backpropagating action potentials were shown to induce supralinear increases in dendritic Ca 2+ , indirectly suggesting a heightened sensitivity in these cells to deviations from homeostatic setpoints (Hage and Khaliq, 2015) . It should be noted however that the impact of pacemaking and Ca 2+ -linked energetic decline is only one component of a multi-faceted intrinsic vulnerability profile, which also includes the large projection area and intense axonal arborization of SNc neurons, expression of the aggregation-prone protein α-synuclein, and the oxidant qualities of cytosolic dopamine (Surmeier et al., 2017; Lieberman et al., 2017; Pacelli et al., 2015; Matsuda et al., 2009; Chu and Kordower, 2007) .
Synaptic specializations & dysfunction in dopamine neurotransmission
Dopaminergic neurons are specialized to receive high volumes of afferent information and synthesize a responsive and advantageous neuromodulatory tone through a large projection area (Beeler and Dreyer, 2019; Tian et al., 2016; Matsuda et al., 2009 ). Important to this is a relative sparsity of bona fide dopamine synapses with traditional presynaptic proteins and clear post-synaptic targets (Descarries et al., 1996; Descarries and Mechawar, 2000; Silm et al., 2019; Liu et al., 2018) . Instead, release sites can be seen in the general vicinity of postsynaptic medium spiny neurons that are putatively being influenced by brain region-specific changes in dopamine tone (Descarries et al., 1996; Cragg and Rice, 2004) . There is considerable redundancy in this system: in rats, one SNc dopamine neuron is estimated to influence~75,000 striatal MSNs (Matsuda et al., 2009 ). Subsequent to this, any given individual striatal MSN is influenced by dopamine released from 95 to 194 dopamine neurons (Matsuda et al., 2009 ). The lack of canonical synaptic release sites is coupled to a low probability of release for dopamine containing vesicles, allowing an accurate scaling of neurotransmitter released as a function of changing firing frequencies (Silm et al., 2019; Pan and Ryan, 2012; Pereira et al., 2016) . Taken together, these data can explain the long-standing observation that dopamine neurons harbor a "reserve pool" of dopamine vesicles that are highly insensitive to stimulation, as well as the more recent finding that up to 60% of dopaminergic synaptic release sites are functionally silent when stimulated (Liu et al., 2018; Pereira et al., 2016; Ewing et al., 1983; Covey et al., 2013) .
Neuronal dysfunction at axonal and terminal release sites is believed to precede somatic dysfunction and degeneration in SNc dopamine neurons (Cheng et al., 2010; Tagliaferro and Burke, 2016; Caminiti et al., 2017; Scott et al., 2010) . As mentioned above, large and highly arborized axons constitute one facet of SNc dopamine neurons' intrinsic-vulnerability profile, putatively through an increase in surface area for active release and reuptake processes with little concomitant increase in cell volume to hold adequate bioenergetic machinery (Pacelli et al., 2015; Matsuda et al., 2009 ). These axons are also unmyelinated, further increasing the energetic demand on the cell (Braak and Del Tredici, 2004; Braak et al., 2003b; Pissadaki and Bolam, 2013) . Supporting this hypothesis, experimental depletion of axonal mitochondria by inhibiting mitochondrial fission induces a retrograde degeneration of SNc dopamine neurons (Berthet et al., 2014) . These data are consistent with proposed mechanisms of pink1-and parkinlinked familial PD, as both genes encode for proteins responsible for regulating mitochondrial fission (Deng et al., 2008; Chung et al., 2016; Buhlman, 2017) .
Studies conducted in vitro examining the staging of α-synuclein aggregation indirectly support the argument for retrograde dysfunction: synaptic and axonal accumulation of insoluble α-synuclein inclusions precede that seen in the soma of cultured mouse hippocampal neurons (Scott et al., 2010; Volpicelli-Daley et al., 2011; Wu et al., 2019) . The physiological role of α-synuclein in synaptic neurotransmission is not fully characterized, although it has been shown that this small (14 kDa) intrinsically-disordered protein senses and binds curved membranes like those of synaptic vesicles (Pranke et al., 2011; Middleton and Rhoades, 2010; Sulzer and Edwards, 2019) . α-synuclein is hypothesized to directly affect vesicular dynamics by organizing exocytotic machinery as well as through direct interactions with vesicles themselves to expand the size of the vesicular fusion pore thereby promoting exocytosis (Logan et al., 2017; Abbineni et al., 2019; Burré et al., 2014; Garcia-Reitböck et al., 2010) . Importantly, synaptic and axonal α-synuclein accumulation lowers the expression of pre-synaptic proteins required for canonical neurotransmission, decreases the frequency of mEPSCs in post-synaptic target neurons, and inhibits vesicle recycling dynamics (Scott et al., 2010; Wu et al., 2019; Busch et al., 2014) . The observed effect of α-synuclein aggregation on pre-synaptic function could carry profound ramifications in any neuronal environment, but the oxidant properties of dopamine may further amplify downstream cellular insults in SNc dopamine neurons (Graham, 1978; Chen et al., 2008; Zhang et al., 2018) . Given the heterogeneity in vesicular dynamics at dopamine release sites, it is possible that either silent release sites harboring stagnant vesicles, or active release sites undergoing near-constitutive release and recycling, may create an environment that facilitates α-synuclein aggregation capable of compromising synaptic function.
The sum total of these factors suggests proper handling of dopamine by SNc neurons at release sites as a critical homeostatic setpoint, deviation from which can disproportionately compromise long-term cell viability. Herein, we aim to outline the major proteins responsible for dopamine homeostasis at release sites in dopamine neurons, with specific attention paid to how they differ between the disease sensitive SNc and relatively robust VTA dopamine neurons. We discuss the basic physiological role, regional differences, and contributions to disease of four key proteins involved in synaptic dopamine synthesis, storage, and recycling. Using that information, we also present a cell-level view of how each individual component's behavior may create a vulnerable SNc dopamine phenotype. Finally, we discuss the benefits and pitfalls of the current state of modeling synaptic physiology in dopamine neurons, and how the use of new temporally and spatially resolved technologies can be applied to remaining knowledge gaps ( Fig. 1 ).
Synaptic regulation of dopamine homeodynamics
Signal termination and recycling of dopamine by the dopamine transporter
The dopamine transporter (DAT, SLC6A3) is a sodium/chloridedependent neurotransmitter transporter that is responsible for terminating dopaminergic signals by reuptaking dopamine molecules released into the extracellular space (Torres et al., 2003) . This process has been argued to be the foremost modulator of brain dopamine tone (Beckstead et al., 2007; Courtney et al., 2012; Cass et al., 1992) . DAT also exhibits efflux, a process in which the direction of dopamine transport is reversed and transporters begin releasing dopamine into the extracellular space (Khoshbouei et al., 2003) . Efflux of DAT is the underlying mechanism of the widely prescribed and abused psychostimulants known as amphetamines (Khoshbouei et al., 2003; Sambo et al., 2017; Freyberg et al., 2016) . DAT is expressed at the cell bodies and along the dendritic field of dopamine neurons, which also serve as locations of dopamine release and signaling (Rahbek-Clemmensen et al., 2017; Chen and Rice, 2001) . However, the precise contributions of DAT-mediated dopamine efflux and reuptake to somatodendritic release are not fully characterized (Falkenburger et al., 2001; Rice Margaret and Patel Jyoti, 2015; Robinson et al., 2019) .
Multiple mutations in the gene encoding DAT (SLC6A3) have been identified in humans. The phenotypic spectrum varies widely and includes: infantile parkinsonism and dystonia, Attention Deficit and Hyperactivity Disorder (ADHD), Schizophrenia, and Autism Spectrum Disorder (Hansen et al., 2014; Kurian et al., 2009; Campbell et al., 2019; Ng et al., 2014; Sakrikar et al., 2012; Mazei-Robison et al., 2008) . Individuals carrying homozygous loss-of-function missense mutations at the DAT allele develop parkinsonian and dystonic motor deficits (known as dopamine transporter deficiency syndrome) as early as one year in age (Kurian et al., 2009; Ng et al., 2014; Kurian et al., 2011) . Currently, symptomatic relief is by-and-large unattainable in these patients due either to a lack of clinical efficacy or the presence of adverse side effects (Ng et al., 2014) . In two individuals, compound heterozygous mutations in the gene encoding DAT gave rise to motor symptoms at three and four years of age (Kurian et al., 2011) . Interestingly, mice that do not express DAT show a transient hyperactive phenotype, but~one-third (36%) of these mice go on to develop severe and progressive motor deficits that result in mortality by one year of age (Cyr et al., 2003; Giros et al., 1996) . Thusly, evidence from both animal models and human mutations establish a critical role of dopamine recycling in maintaining long-term brain dopamine levels.
It is important to note that decreased DAT expression or DAT knockout yields protection against experimental dopaminergic neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyradine (MPTP) and 6-hydroxy-dopamine (6-OHDA), but these molecules are transported into cells by DAT itself (Bezard et al., 1999) . Therefore, DATdeficient animal models of PD are unlikely to relate to the innate pathogenic course of PD in humans (Javitch et al., 1985) . However, DAT activity in the SNc vs VTA has been examined to determine if differential transport activity may contribute to the selective sensitivity of SNc cells. Indeed, data from SNc-or VTA-enriched neuronal cultures have shown that SNc neurons exhibit higher uptake of a DAT-specific fluorescent molecule (Lieberman et al., 2017) . This correlates with what is known about in vivo DAT behavior in rats, in which the clearance rate of dopamine is greater in SNc efferent regions (i.e. striatum) than in VTA efferent regions (i.e. nucleus accumbens) (Cass et al., 1992; Stamford et al., 1988; Suaud-Chagny et al., 1995) . These data imply that the potential role of neurotoxin accumulation through DAT would be expected to impact SNc dopamine neurons more than their VTA counterparts. And while it is notable that neurotoxin induced parkinsonism has been documented in humans, and occupational exposure to neurotoxic pesticides increases the risk of developing PD, the degree to which toxin uptake contributes to the death of SNc cells on a large scale with no conspicuous exposure may be difficult to determine (Langston et al., 1983; Dorsey et al., 2018; Van Maele-Fabry et al., 2012) .
Productionthe role of tyrosine hydroxylase in dopamine homeostasis
Tyrosine hydroxylase (TH) is the rate limiting enzyme of the dopamine synthesis pathway, but has also long served scientific ends as the gold standard for immunolabeling of dopamine neurons (Pearson et al., 1979; Gaspar et al., 1983; Pickel et al., 1981) . In humans, TH is present in cell bodies, dendrites, axonal projections, and terminal release sites of both SNc and VTA dopamine neurons (Reyes et al., 2012; Kordower et al., 2013; Sesack et al., 1995) . This suggests that dopamine is not synthesized in any one compartment of dopamine neurons but can be made locally for release throughout the cell. However, evidence from model systems reveals subcellular specialization does occur, with TH enrichment shifting from cell bodies to terminals during the early stages of growth (~DIV 3) in organotypic rat cultures (Lyng et al., 2007) . This correlates with what is known about dopamine concentrations in fully developed ex vivo mouse brain slices, wherein the measured dopamine content is~20 fold higher in the striatum relative to the SNc and VTA (Ford et al., 2010) . The relative enrichment of TH in terminals vs. soma remained detectable in 12 month old rats, with the striatum exhibiting the highest amount of TH protein measured (Salvatore and Pruett, 2012) . This sheds light on a potential impact of Repeated exposure to large increases in intracellular Ca 2+ ions induce mitochondrial damage, leading to compromised bioenergetics. Cytosolic dopamine (orange) is hypothesized to be higher in disease sensitive neurons than non-sensitive counterparts, resulting in increased levels of oxidized dopamine metabolites (red) capable of causing damage to intracellular and transmembrane components. Additionally, dopamine transporters at release sites may uptake environmental and dietary neurotoxins at a level correlated with transporter expression. B. The Ca 2+ binding protein calbindin, coupled with less reliance on Ca 2+ for pacemaking, limits damage to axonal mitochondria preventing bioenergetic failure. Aldehyde dehydrogenasean enzyme the converts aldehyde groups to carboxylic acidacts on selected dopamine oxidation metabolites including dopamine −3,4,-dihydroxyphenylacetaldehyde (DOPAL) to reduce ROS generation and subsequent cell damage.
de novo dopamine production on cellular vulnerability, as the most THenriched brain region maps onto the most sensitive to degeneration in PD. Relative TH abundance shows an opposite pattern in the soma though: tissue obtained from the VTA contained~3 fold higher levels of TH than tissue obtained from SNc counterpart regions (Salvatore and Pruett, 2012) . The nucleus accumbens (NAc), a major projection region of the VTA immediately ventral to the striatum, showed similarly low levels of TH to that measured in the soma of SNc neurons (Salvatore and Pruett, 2012) . Taken together, these data tell us that the developmental shift of TH enrichment from somatic to terminal regions occurs strongly in SNc dopamine neurons (~7 fold higher TH in striatum than SNc), but VTA counterparts maintain an opposite, but more modest, enrichment of TH at the soma (~2.5 fold higher TH in VTA than NAc) (Salvatore and Pruett, 2012) . However, physiological and pathological ramifications of this paradoxical TH distribution remain incompletely understood. Taken in conjunction with the fact that SNc neurons exhibit higher DAT uptake activity, it is potentially the case that these cells operate at a higher dopamine "steady-state" concentration than VTA dopamine neurons. This idea is supported by intracellular patch electrochemistry measurements done in cultured dopamine neurons, in which SNc neurons harbor two to three fold higher levels of cytosolic dopamine than VTA neurons (Mosharov et al., 2009 ). Whether or not these somatic measurements would remain consistent with free dopamine levels in terminal fields is not yet known. Regardless, these data suggest that SNc dopamine neurons may not only be subject to relatively higher levels of oxidative damage due directly from dopamine's oxidant potential, but may also be more sensitive to any insult that would disrupt or diminish dopamine levels in these cells.
Tyrosine hydroxylase deficiency (THD), a rare autosomal recessive disorder caused by loss-of-function mutations in the gene encoding TH, most commonly presents as an early onset motor disease responsive to exogenous L-DOPA treatment (Grattan-Smith et al., 2002) . Severity of symptoms follows a gene dose-dependent pattern, with homozygous mutation carriers presenting with sever deficits during infancy, while heterozygotes will typically not show symptoms until adolescence (Willemsen et al., 2010) . THD is almost exclusively caused by missense mutations in the TH gene or promoter, suggesting that mutations that induce a more drastic phenotype are heavily selected against and will result in lethality before a disorder can be identified (Willemsen et al., 2010) . Lending credence to this hypothesis is data from transgenic mouse models, in which full knockout of the TH gene resulted in severe embryonic lethality (Zhou et al., 1995; Kobayashi et al., 1995) . Further, transgenic mice expressing hypofunctional TH exhibited gross motor defects despite anatomically normal dopaminergic innervation (Althini et al., 2003) .
THD is a rare disorder, however, a loss of TH immunoreactivity without a concomitant loss of dopamine neurons is a common observation across multiple disease states. For example, post-mortem samples from individuals with PD show that melanized SNc dopamine neurons lose their TH immunoreactivity before the cell degenerates per se 137 . A similar pattern was observed in mice overexpressing the HIV-1 associated protein Tat: Tat overexpression induced a loss of SNc TH immunoreactivity yet a general neuronal marker (NeuN) revealed that there was no gross loss of neurons in this region (Miller et al., 2018) . Mechanistically, the latter case can be explained by a direct inhibition of TH gene expression by HIV-1 Tat (Zauli et al., 2000) . In PD however, the cascade of events that precede and induce a loss of TH immunoreactivity is poorly understood. Similarly, it remains unclear what the functional properties of these TH-negative melanized dopamine neurons are or if they can be rescued to restore their TH expressing phenotype.
Packaging cytosolic dopamine via vesicular monoamine transporter 2
Vesicular monoamine transporter 2 (VMAT2, SLC18A2) acts to sequester cytosolic dopamine into vesicles for exocytotic release into the extracellular space (Eiden and Weihe, 2011) . In both the NAc and dorsal striatum, VMAT2 is localized to small synaptic vesicles (SSVs) where it packages dopamine for canonical vesicular exocytosis (Nirenberg et al., 1996) . In dopaminergic cell bodies, VMAT2 localization is seen on lateral saccules of the golgi apparatus and tubulovesicular organelles resembling smooth endoplasmic reticulum (sER) (Nirenberg et al., 1996) . In mesolimbic dopamine neurons (ie. NAc terminals / VTA cell bodies) VMAT2 is also observed on dense core vesicles, though these vesicles are absent in the SNc (Nirenberg et al., 1997) . Similar to the above described TH expression data, quantitative analysis suggests that VTA cell bodies harbor significantly higher amounts of VMAT2 than their SNc counterparts (Nirenberg et al., 1996) . As described earlier, it is theorized that one factor contributing to the heightened vulnerability of SNc dopamine neurons is a high cytosolic dopamine concentration (Mosharov et al., 2009) . A relative scarcity of SNc VMAT2 expression at cell bodies may provide a mechanism underlying this phenomenon, however it is also possible that the concomitant lower TH expression in the SNc dopamine neurons compensates for lower VMAT2 levels.
Similar to TH, mutations in the gene encoding VMAT2 are rare and individuals with these mutations present with a severe early-onset parkinsonism (Rilstone et al., 2013) . These symptoms were coupled to global developmental deficits, sleep disruption, and reduced urinary dopamine (Rilstone et al., 2013) . In contrast to TH mutations, treatment with exogenous L-DOPA induced a worsening of symptoms which returned to baseline levels when treatment was halted (Rilstone et al., 2013) . Functionally, this mutation was shown to result in a hypofunctional transporter, and treatment with a dopamine receptor agonist provided substantial and sustained improvements in symptoms (Rilstone et al., 2013) . In addition to bona fide mutations, rare single nucleotide polymorphisms (SNPs) have been identified in the SLC18A2 gene in individuals with PD and micropthalmia (Patel et al., 2018; Burman et al., 2004) .
VMAT2 knockout mice survive embryonic development and have morphologically normal DA neurons, but move and feed little and die shortly after birth (Fon et al., 1997; Wang et al., 1997) . In contrast, animals heterozygous for the knockout express~50% of the VMAT2 seen in wild-type counterparts and exhibit a normal lifespan (Fon et al., 1997; Takahashi et al., 1997) . VMAT2 heterozygous knockout animals display comparatively subtle dopaminergic defects however, including reduced reward conditioning in response to amphetamine and increased vulnerability to the dopaminergic neurotoxin MPTP (Takahashi et al., 1997) . To bridge the gap between the poorly viable full knockouts, and the largely unperturbed heterozygotes, a VMAT2 deficient mouse line expressing~5% of wild-type levels was later generated and characterized (Caudle et al., 2007) . These VMAT2 deficient mice were grossly normal and lived into adulthood, but exhibited age-dependent motor deficits and dopaminergic degeneration (similar to that seen in PD) (Caudle et al., 2007) . Unlike the cases observed in humans with mutations in VMAT2, treatment with exogenous L-DOPA led to a reversal of the motor deficits observed in aged VMAT2 deficient mice (Caudle et al., 2007) . Also of note here, is the coexpression of VGLUT2 in midbrain dopamine neurons, a vesicular transmitter for the neurotransmitter glutamate. It has been observed that neurotoxic insult increases the proportion of SNc dopamine neurons that coexpress VGLUT2, and overexpression of VGLUT2 induces dopaminergic neurodegeneration and concomitant motor deficits (Steinkellner et al., 2018) . However, the mechanisms of VGLUT2-induced neurotoxicity, and how an interplay with VMAT2 contributes to this, are not fully characterized.
Regulation of neuronal firing and extracellular DA by D2 autoreceptors
Dopaminergic neurons express D2 receptors (D2Rs) that act as a negative feedback conduit to reduce neuronal firing when activated by extracellular dopamine (Ford, 2014; Lacey et al., 1987; Aghajanian and Bunney, 1977) . Two isoforms of D2Rs generated through alternative splicing -D2 Long and D2 Shortare expressed in the mammalian CNS (Giros et al., 1989) . Data from D2 Long knockout and total D2R knockout mice suggest that presynaptic autoregulation of dopamine neurons is predominantly carried out by the D2 Short isoform (Usiello et al., 2000; Boulay et al., 1999) . These D2 Short autoreceptors are coupled to Gprotein activated inwardly-rectifier K + (GIRK) channels which hyperpolarize the cell and inhibit firing (Lacey et al., 1987; Beckstead et al., 2004; Perra et al., 2011) . Membrane hyperpolarization has also been shown to increase surface DAT, suggesting a dynamic feedback system specialized for large changes extracellular dopamine (Richardson et al., 2016) . This is directly supported by in vivo data showing that while dopamine reuptake is accelerated under continuous stimulation to meet demand, there is no such acceleration in mice lacking D2Rs (Benoit-Marand et al., 2011) . Additional molecular and biophysical underpinnings of D2Rs positive modulation of DAT-mediated uptake have also been identified in heterologous expression systems (Mayfield and Zahniser, 2001; Lee et al., 2007; Bolan et al., 2007) . D2R activation has also been shown to reduce Ca 2+ influx through voltage-dependent Ca 2+ channels in dopamine neurons, thereby limiting vesicular neurotransmitter release (Cardozo and Bean, 1995) . The combination of firing inhibition, uptake enhancement, and reduction of Ca 2+ influx constitutes a multi-pronged response through which D2 autoreceptor activation can reduce extracellular dopamine levels (Wu et al., 2002; Cardozo and Bean, 1995) . Notably, the D2 antagonist sulpiride is commonly used as an antipsychotic in the treatment of schizophrenia, although its clinical efficacy has been debated (Wang and Sampson, 2014) .
D2R activation threshold and relative contribution to extracellular dopamine levels vary considerably between brain regions and model species (Beckstead et al., 2007; Courtney et al., 2012; Rice and Cragg, 2008; Lammel et al., 2008) . Studies have shown distinct D2R-mediated autoregulation when comparing SNc and VTA dopamine neurons (Cragg and Greenfield, 1997) . Results gathered using ex vivo voltammetry reveal that while terminal regions of SNc and VTA dopamine neurons are strongly regulated by D2R activation, dopamine release at the cell bodies is only altered by D2R activity in the SNc (Cragg and Greenfield, 1997; Iravani et al., 1996) . This was further dissected using single-cell electrophysiology, which identified mesocortical (VTA to prefrontal cortex) dopamine neurons as the only subtype that did not exhibit a GIRK2-mediated hyperpolarizing current in response to D2R activation (Lammel et al., 2008) . These mesocortical neurons appear to map to a location of the VTA that was identified as harboring TH (+)/D2(−) dopamine neurons, potentially explaining their lack of autoinhibition (Li et al., 2013) . A second potential contributor to this is the relatively higher expression of GIRK2 in SNc cell bodies than in the VTA (Fu et al., 2012; Lammel et al., 2008; Thompson, 2005) . Similar to calbindin, this is consistent with a developmentally-determined gradient of GIRK2 expression, although in this case enriched GIRK2 expression maps to disease-sensitive SNc dopamine neurons (Di Salvio et al., 2010) . The VTA also differs in its expression of the GIRK3 subunit, which can form heteromeric channels with GIRK2 that are less efficacious at coupling to D2Rs (Inanobe et al., 1999; Cruz et al., 2004; Munoz et al., 2016) . One last potential difference between the SNc and VTA is D2-mediated downregulation of TH (Kehr et al., 1972; Anzalone et al., 2012) . Due to the contrasting subcellular distribution of TH and graded expression of D2R in the SNc vs. VTA, it is likely that D2-TH interactions asymmetrically shape dopamine synthesis and release in the two regions (Salvatore and Pruett, 2012; Anzalone et al., 2012) . Owing in part to the existence FDA-approved therapeutics that can safely and specifically target D2Rs, these receptors may prove a potent therapeutic target to exogenously modulate dopamine homeostasis at release-sites and cell-wide.
Tying together synaptic phenotype of midbrain dopamine neurons
Ontology begets physiologygraded heterogeneity in midbrain dopamine neurons
As alluded to earlier, multiple disease relevant proteins (ie. calbindin, GIRK2) exhibit an expression gradient across midbrain dopamine neuron populations (Fu et al., 2012; Dopeso-Reyes et al., 2014; Reyes et al., 2012) . This strongly suggests regions are specified during early development, owing to the role of signaling centers and diffusion gradients in brain organization (Ashe and Briscoe, 2006; Blaess and Ang, n.d.) . Indeed, the developmental fate of dopamine neurons appears to be established prior to birth and heavily regulated by numerous transcription factors (TFs) after birth (Blaess and Ang, n.d.; Veenvliet and Smidt, 2014) . Non-TF proteins that exhibit an expression gradient can readily be correlated with the relative disease sensitivity of dopamine neurons, albeit with different degrees of causality suggested (Liang et al., 1996; Reyes et al., 2012; Liu et al., 2014) . However, a direct role of TF-mediated maintenance of dopamine neurons has also been proposed and mutations in these genes have been linked to PD (Doucet-Beaupré and Lévesque, 2013) . Irrespective of any individual component's causality, understanding the dopaminergic nuclei of the midbrain to be organized in a graded fashion may provide important clues as to how a subset of SNc neurons have evolved to be so susceptible to neurodegeneration.
The nigrostriatal subpopulations of dopamine neurons that appear most sensitive to degeneration in human diseases states exist at an anatomical boundarythe ventrolateral-most portion of the SNc (Damier et al., 1999) . This pattern of loss in the SNc has also been mapped onto animal models of dopaminergic degeneration, with the dorsolateral region of the SNc proving most vulnerable (Poulin et al., 2014) . These neurons are likely to comprise one end of developmental expression gradients, which is partly supported by rodent immunolabeling data of calbindin expression (absent in these neurons), and GIRK2 (enriched in these neurons) (Fu et al., 2012) . And much like the expression of specific proteins, physiological processes can be observed as changing through dopamine neurons in a graded fashion. For example, the tonic firing rate of dopamine neurons is highest in the most lateral subset (lateral SNc), and lowest in the most medial subset (medial VTA) (Krashia et al., 2017) . This is coupled to an increased membrane resistance, lowered membrane capacitance, and smaller cell size in the medial VTA compared with it's lateral SNc counterparts (Krashia et al., 2017) . Sensitivity to degeneration also presents as a gradient throughout midbrain dopamine neurons (Poulin et al., 2014; Di Salvio et al., 2010) . However, the dichotomous readout of living vs. dead cells, or TH immunoreactive vs. non-immunoreactive, may preclude the appreciation of graded changes in dopamine neuron health and pathophysiology. Thusly, processes that can be studied in living dopamine neurons along a continuous spectrum -including but not limited to synaptic dopamine handling and vesicular dynamicsmay allow for a better understanding of which cell populations undergo changes in age-related dopaminergic neurodegeneration like PD.
Potential contributions of synaptic phenotypes to selective dopaminergic degeneration
Adding in the above described synaptic phenotype data, SNc terminal fields harbor the highest concentration of TH observed across all regions studied, but relatively low levels of somatic TH expression (Salvatore and Pruett, 2012) . Although this data does not specify a location of terminal fields that could provide information about SNc subpopulations, it is not unreasonable to think that similar to other graded identifiers in dopamine neurons, the SNc neurons most susceptible to degeneration exist at one extreme. This leads to the hypothesis that the most sensitive SNc neurons will express high levels of TH in terminals and suggests a heightened reliance on de novo dopamine synthesis to carry out signaling. It should follow then, that these neurons will harbor similarly high amounts of VMAT2 in terminals, to manage de novo dopamine packaging, and lower DAT expression or activity due to less reliance on transmitter recycling. However, the opposite is true for DAT expression -SNc neurons show greater DATmediated substrate uptake when measured at the cell body, and their projection regions show greater rates of dopamine clearance following release (Lieberman et al., 2017; Cass et al., 1992; Stamford et al., 1988; Suaud-Chagny et al., 1995) .
This now establishes SNc dopamine neurons as a population that signals using relatively more dopamine resources than their VTA counterparts (increased production signified by TH expression, increased reuptake and recycling signified by DAT behavior). Therefore, these neurons can be phenotyped as "dopamine-high" (DA high ) cells, characterized by relatively heightened levels of steady-state dopamine production, packaging, and recycling. This phenotype is also indirectly supported by single-cell cytosolic dopamine measurements in SNc and VTA specific mouse cultures (Mosharov et al., 2009) . A DA high phenotype may underlie these neurons' higher spontaneous firing frequency, potentially a mechanism to purge adequate amounts of de novo synthesized dopamine and prevent cytosolic accumulation. Given the high tonic firing rate and TH enrichment in terminals, it is also plausible that the MSNs receiving input from DA high SNc neurons are adapted to relatively high tonic concentrations of dopamine, which as described above, may render them disproportionately sensitive to any insults that disrupt dopamine handling. If true however, therapeutic restoration of dopamine signals would require careful determination of the appropriate homeostatic setpointeither a minimal concentration that can promote appropriate brain signaling while preserving cell health, or a higher concentration that aims to re-establish physiological levels. This may be difficult to determine owing the earlier described redundancy in dopaminergic connections, however understanding how different dopamine setpoints alter neuronal physiology and response to insult through time may prove critical to finding an effective degeneration modifying agent.
Modeling the dopamine handling phenotypes of the SNc and VTA
As outlined, synaptic dopamine handling can be linked to dopaminergic sensitivity to degeneration as well as other dopamine related disorders (Mosharov et al., 2009; Lieberman et al., 2017; Sakrikar et al., 2012) . This is also an appealing avenue of investigation due to a growing toolbox of optical sensors and fluorescent dyes generated to examine dopamine neurotransmission. These include probes to measure vesicular release and recycling, DAT trafficking and uptake, and dopamine receptor activation (D1R and D2R) (Silm et al., 2019; Pereira et al., 2016; Karpowicz et al., 2013; Patriarchi et al., 2018; Sun et al., 2018; Eriksen et al., 2009) . Depending on the model system, these tools provide minimally-invasive measures of synaptic dopamine dynamics. This can be conducted using a large field of view to compare anatomically distributed dopamine neurons, or with resolution that reaches single release sites in more defined anatomical areas (Pereira et al., 2016; Patriarchi et al., 2018) .
A remaining challenge in studying age-dependent dopamine loss is the limited availability of animal models that adequately capture the complexity of processes that take place over decades in the human brain (Surmeier et al., 2017) . Neurotoxins selective for dopamine neuronsmost commonly MPTP and 6-OHDA -have been exploited in mice, rats, and non-human primates to investigate pathophysiological processes involved in dopaminergic neurodegeneration (Bezard et al., 1997; Alvarez-Fischer et al., 2008; Porras et al., 2012) . And while meaningful refinements have been made, these neurotoxins are generally thought to induce a more acute cascade of pathophysiology preceding cell death than that which may take place over a full lifespan in the human brain (Willard et al., 2015) . Also as described, both of these toxins have been shown to be transported into dopamine neurons via uptake by DAT, preventing examination of endogenous components of DAT activity to neurodegeneration (Javitch et al., 1985; Redman et al., 2006) . Thusly, it remains difficult to know how closely the cell death seen in these models matches that which takes place in human neurodegeneration, and how a therapeutic window can be scaled from these models to human disease. However, dietary and peripheral neurotoxin models that more closely replicate patterns of pathology progression seen in human disease represent a promising and growing field to investigate dopamine neurodegeneration (Naudet et al., 2017; Kim et al., 2019) .
In addition to dietary and peripheral insult models, transgenic mouse models have become an important tool for investigating gradual and SNc-specific dopamine neuron cell-death (Raza et al., 2019; Dauer and Przedborski, 2003; Janus and Welzl, 2010; Wong et al., 2002) . A subset of these models are based around genetic mutations that have been linked to PD dopamine neurodegeneration in humans (Subramaniam et al., 2014a; Parrado-Fernández et al., n.d.; Ip et al., 2017) . Transgenic models with disrupted mitochondrial physiologymost prominently the MitoPark mouse strainhave been generated to mimic the energetic burdens hypothesized to impinge on SNc dopamine neurons (Branch et al., 2016; Ekstrand and Galter, 2009; Farrand et al., 2016; Ghaisas et al., 2019) . Briefly, deletion of the mitochondrial transcription factor A from dopamine neurons results in gradual and SNc-selective dopamine neuron degeneration (Ekstrand and Galter, 2009 ). These mice present with concomitant gradual motor deficits and intraneuronal inclusions, though these inclusions are dissimilar to αsynuclein-containing LBs (Ekstrand and Galter, 2009 ). This raises an important caveat regarding many genetic modelswhile it is common to reproduce a single or small subset of core PD features, it has proven difficult to create a mouse model that encompasses all of the pathological aspects of human PD (Surmeier et al., 2017; Raza et al., 2019) . The combination of multiple mutations, or combined treatment with neurotoxins on transgenic backgrounds, are currently being used to better replicate PD-linked pathology and age-dependent dopamine neurodegeneration (Sliter et al., 2018) .
More recently, human neurons generated in vitro from induced pluripotent stem cells (iPSCs) have risen to prominence as powerful model systems to investigate cellular mechanisms of dopamine neuron degeneration (Kouroupi et al., 2017; Chung et al., 2016; Burbulla et al., 2017) . Human dopamine neurons generated from individuals with idiopathic or familial PD can be studied longitudinallyan imperfect but plausible and controllable replication of biological agingat resolutions previously only possible in animal models or immortalized cell lines (Burbulla et al., 2017) . New technology that preserves agerelated traits of in vitro human neurons by circumventing the reprogramming to pluripotency will potentially enable experiments on human dopamine neurons through aging and neurodegenerative progression (Kim et al., 2018) . More generally, as probes, imaging methods, animal models, and human in vitro preparations continue to advance, subtle changes in synaptic dopamine homeostasis will be trackable in ways that have until now been unachievable. Given the retrograde pattern of degeneration theorized to take place in dopaminergic neurodegeneration, it is possible that a therapeutic intervention targeting synaptic dysfunction may be sufficient to prevent the backpropagation of these processes to the cell body, preserving the longevity of SNc dopamine neurons through aging and disease. These targets are made more promising by the existence of numerous FDA-approved compounds that can target dopamine handling proteins at release sites. Early pathophysiological changes detected at the synaptic level may be more reversible than dysfunction that has reached a cell-wide scale. Longitudinal sub-cellular data on dopamine handling represents potential answers to the critical knowledge gap regarding early processes underlying dopamine neurodegeneration, the closure of which may ultimately reveal therapeutic targets to achieve dopamine neuroprotection in humans.
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